Furthermore, SGLT2 inhibition also has hepatoprotective effects by reducing fatty liver content and improve liver biology in patients with T2DM and non-alcoholic fatty liver disease (Scheen 2019; Schork et al. 2019). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.